Weight Loss ETF THNR Reweights Its Index: What's Up & Down The index saw nine of its holdings increase in weight, while eight dropped. Notable names among the risers include AstraZeneca PLC (AZN)which moved from a 5.3% weight to a 7.1% weight after rebalancing. Others that rose in weight within the THINR index include Novo Nordisk A/S (NVO)and Arrowhead Pharmaceuticals Inc (ARWR). Notably, among decreasing weights in the index, Eli Lilly & Co. (LLY)dropped from 12.4% to 10.5% in the rebalance. Other notable ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is one of Billionaire Ken Fisher’s 15 Most Notable Moves for 2026. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is a relatively recent addition to the 13F portfolio of Fisher Asset Management. The fund first disclosed a stake in the firm in filings for the second quarter of 2024, comprising close to 12,000 shares purchased at an average price of more than $24. In the ensuing six quarters, the fund has aggressively added to this stake, with notable additions o ...

Core Insights - Arrowhead Pharmaceuticals has transitioned into a commercial-stage organization following the FDA approval of its first medicine, REDEMPLO (plozasiran), marking a significant strategic turning point [1] - The company reported a substantial increase in revenue and net income for FQ1 2026, driven by collaborations with Novartis and Sarepta Therapeutics [4] Group 1: Company Developments - Arrowhead achieved over 100 initial prescriptions for REDEMPLO in the US and established a dedicated patient support program [2] - The company initiated a Phase 1/2a trial for ARO-DIMER-PA, the first dual-function clinical candidate targeting two genes in one molecule [2] - Arrowhead reported positive interim data from its obesity programs, particularly with ARO-INHBE showing significant weight loss when combined with tirzepatide [2] Group 2: Financial Performance - Arrowhead's revenue for FQ1 2026 reached $264 million, a significant increase compared to the previous year [4] - The company reported a net income of $30.8 million for the quarter, contrasting sharply with a loss of $173.1 million in the same period last year [4] - The revenue surge was attributed to a $200 million upfront payment from a collaboration with Novartis and a $200 million milestone payment from Sarepta Therapeutics [4] Group 3: Product Pipeline - Arrowhead's pipeline includes key products such as Plozasiran, Zodasiran, ARO-DIMER-PA, and ARO-PNPLA3, focusing on treatments for intractable diseases [5]

Investment Rating - The report does not explicitly state an investment rating for the small nucleic acid industry Core Insights - Small nucleic acid drugs have transitioned from technical validation to commercial realization, with projected sales of approximately $3.1 billion for ASO and $4.2 billion for siRNA by 2025 [3] - The development paths of ASO and siRNA are shaped by their mechanistic differences, with ASO utilizing a single-strand structure for direct delivery into target cells, while siRNA relies on carrier systems for effective delivery due to its larger size and strong negative charge [3] - Continuous evolution in chemical modifications and delivery platforms has improved the stability, targeting, safety, and convenience of small nucleic acid drugs, expanding their application from rare diseases to chronic conditions [3] - Current advancements in liver-targeting technologies are paving the way for the next phase of delivery to extrahepatic tissues, with future valuations of small nucleic acid companies focusing on platform capabilities and expansion into chronic disease treatments [3] Summary by Sections Small Nucleic Acids Unlock Gene Expression Regulation - Small nucleic acid drugs can target previously undruggable proteins by intervening at the gene expression level, significantly broadening the potential therapeutic targets [9][11] Pathways to Small Nucleic Acid Drug Development - The report outlines the dual pathways of ASO and siRNA, highlighting their distinct mechanisms and therapeutic applications [12][30] Mechanistic Differences: ASO vs. siRNA - ASO employs RNase H-mediated degradation and splicing regulation to inhibit protein expression, while siRNA utilizes the RISC mechanism for mRNA degradation [20][26] Chemical Modifications and Stability - The report details the evolution of chemical modifications across four generations, enhancing the stability and specificity of ASO and siRNA [32][36] Delivery Breakthroughs - The challenges of delivering small nucleic acids across cellular barriers are discussed, emphasizing the need for effective delivery systems [40][44] Safety Optimization - Innovations in toxicity management for ASO and siRNA are crucial for supporting long-term use and chronic disease management [62][64] Commercialization and Boundary Expansion - The report emphasizes the transition from liver-targeted therapies to exploring delivery strategies for other tissues, indicating a strategic shift in the industry [60][61]

Arrowhead Pharmaceuticals Conference Call Summary Company Overview - **Company**: Arrowhead Pharmaceuticals (NasdaqGS:ARWR) - **Event**: 2026 Conference at the Leerink Partners Global Healthcare Conference - **Date**: March 09, 2026 Key Points Pipeline Developments - **SHASTA-3 and SHASTA-4**: Phase 3 studies for Plozasiran in the SHTG population expected to read out in Q3 2026, with last patient visit in June [11] - **Dimer/Bispecific Data**: First data from a bispecific RNA molecule targeting both PCSK9 and APOC3 for mixed hyperlipidemia patients anticipated in Q3 2026 [11] - **ARO-MAPT**: First CNS target data expected towards the end of Q3 2026, focusing on tau reduction [12] - **Obesity Targets**: Updates for ARO-ALK7 and ARO-INHBE expected in the second half of 2026, with ongoing data collection [13][14] Clinical Insights - **Inhibin E**: Early data shows promising fat redistribution and significant liver fat reduction (76.7%) in obese diabetic patients when combined with tirzepatide [18] - **ALK7**: Early indications of good knockdown in fat biopsies, with further data needed to assess its potential [20] - **Market Size**: The clinically defined FCS market may include tens of thousands of patients with triglycerides above 880 and a history of pancreatitis or abdominal pain [25] Commercial Strategy - **FCS Launch**: Rapid launch with over 100 prescriptions received, including switches from competitor Ionis [24] - **SHTG Market**: Anticipated top-line readout in Q3 2026, with plans to file a supplemental NDA (sNDA) in Q4 2026 [27] - **Pricing Strategy**: Initial focus on high-risk individuals with triglycerides above 880, estimating a target population of 750,000 to 1 million [28] Regulatory Considerations - **AP Risk**: Improvement in acute pancreatitis (AP) risk is not necessary for U.S. regulatory approval, but may be critical in Europe [30][34] - **Most-Favored-Nation Policy**: Current uncertainty may affect international pricing strategies, leading to a preference for retaining control over ex-U.S. markets [46][49] Competitive Landscape - **Innovation Focus**: Emphasis on expanding RNAi technology beyond liver diseases to various cell types, with ongoing clinical studies in multiple areas [56][66] - **Dimer Development**: The potential for synergistic effects in dimer constructs, particularly with targets like APOC3 and PCSK9, is being explored [72] Future Outlook - **Expansion Plans**: Anticipation of new cell type access every 18-24 months, with ongoing studies in CNS and pulmonary applications [66][69] - **Data Validation**: Upcoming data from ARO-MAPT and bispecifics expected to validate the platform and inform future target selections [68] Additional Insights - **Patient Convenience**: The use of prefilled syringes for FCS and auto-injectors for SHTG is expected to enhance patient adherence [40] - **Market Dynamics**: Physicians are reportedly switching to Arrowhead's products due to better activity and safety profiles compared to competitors [41] This summary encapsulates the critical developments and strategic insights from Arrowhead Pharmaceuticals' conference call, highlighting the company's focus on innovation, pipeline advancements, and market positioning.

Arrowhead Pharmaceuticals FY Conference Summary Company Overview - **Company**: Arrowhead Pharmaceuticals (NasdaqGS:ARWR) - **Focus**: RNA interference (RNAi) technology with a broad pipeline of drug candidates, particularly in cardiometabolic diseases and central nervous system (CNS) disorders [2][3] Key Highlights - **Pipeline**: Approximately 21-22 drug candidates currently in clinical studies, with a strong emphasis on cardiometabolic conditions, including obesity [2] - **CNS Platform**: Introduction of a new CNS platform allowing for subcutaneous injections to address CNS disorders, with the first candidate ARO-MAPT targeting Alzheimer's disease [3][4] Upcoming Milestones - **Phase 3 Programs**: Expected readouts in Q3 2026 for SHASTA-3 and SHASTA-4, focusing on plozasiran, a triglyceride-lowering drug for patients with severe hypertriglyceridemia (SHTG) [3][4] - **CNS Data**: Anticipated data readout for ARO-MAPT in late Q3 or early Q4 2026, focusing on tau protein knockdown [5] - **Obesity Programs**: Additional data from ARO-INHBE and ARO-IL27 programs expected later in 2026, with a focus on adipose tissue targeting [6] Product Launch and Market Strategy - **Waylivra Launch**: Approved for familial chylomicronemia syndrome (FCS) with 100 prescriptions in the first 10 weeks, indicating a faster-than-expected launch [7][9] - **Pricing Strategy**: Priced at $60,000 per year, justified by the potential to reduce acute pancreatitis events in high-risk patients [17][19] - **Value Proposition**: Emphasizes the drug's ability to significantly lower triglyceride levels (around 80% reduction) compared to competitors [10][14] Competitive Landscape - **Differentiation**: Waylivra shows superior efficacy with no reported hypersensitivity or thrombocytopenia compared to Ionis' olezarsen, which has a higher non-responder rate [14][15] - **Market Positioning**: Aiming to establish a strong foothold in the high-risk population with a compelling clinical profile [19][20] Clinical Data Expectations - **SHASTA-3 and SHASTA-4**: Anticipated triglyceride reductions in the high 60s to low 70s percentage range, with a focus on translating these reductions into lower acute pancreatitis rates [22][23] - **Safety Monitoring**: Utilizing modified Atlanta criteria for characterizing acute pancreatitis events in clinical trials [26] Future Directions - **Dimer Development**: Exploring the combination of GalNAc siRNAs for mixed hyperlipidemia, targeting both LDL and triglycerides [46][47] - **Expansion into Other Markets**: Potential future studies in non-alcoholic fatty liver disease (NAFLD) and metabolic-associated steatotic liver disease (MASH) [40][46] Financial Position and Collaborations - **Current Financial Health**: Strong position with no immediate need for new partnerships; focus on existing collaborations and internal development [57][59] - **Future Collaborations**: Limited appetite for new partnerships in the near term, with a focus on maximizing current assets [59] Conclusion Arrowhead Pharmaceuticals is poised for significant developments in 2026, with a robust pipeline and strategic focus on cardiometabolic diseases and CNS disorders. The company is leveraging its RNAi technology to address unmet medical needs while maintaining a competitive edge in the market through innovative pricing and product differentiation.

Investment Rating - The industry investment rating is "Strong Outperform" and is maintained [1] Core Insights - siRNA drugs have significant mechanism advantages, with delivery as the core technology. Compared to traditional small molecules and biologics, siRNA drugs can precisely silence pathogenic proteins, degrade effectively, and have a long duration of action, making them a popular direction for new drug development. The core technology focuses on modification and delivery, with liver-external delivery being the current breakthrough focus [2][12] - Overseas giants are entering a harvest period, awaiting proof of concept (POC) for liver-external delivery. Alnylam's GalNAc liver-internal delivery has become the "standard answer" due to its high delivery efficiency and specificity. Other companies like Arrowhead and Dicerna are advancing in clinical stages or commercialization for cardiovascular targets, while liver-external organ targets are still in early development [3][41] - Domestic siRNA drug development is flourishing, with various directions from startups and major pharmaceutical companies. Domestic firms are becoming significant players in the global siRNA arena, with strong business development (BD) willingness from multinational corporations (MNCs) in the liver delivery space. New directions include dual-target and liver-external delivery, narrowing the gap with overseas competitors and potentially leading the industry [4] Summary by Sections siRNA Drug Mechanism Advantages - siRNA drugs can precisely silence pathogenic proteins and have a long duration of action, making them a hot direction for new drug development. The mechanism relies on the RISC complex to degrade target mRNA, with a typical structure of double-stranded RNA [10][12] - The delivery system is crucial for siRNA drug development, as siRNA is hydrophilic and requires specific delivery systems to enhance tissue accumulation and cellular penetration [23][24] Overseas Giants Entering Harvest Period - Alnylam is a pioneer in the siRNA industry, having developed the GalNAc delivery system, which has proven effective in human trials. The company has successfully commercialized several products and is expanding its pipeline in cardiovascular, metabolic, and CNS fields [43][53] Domestic siRNA Drug Development - Domestic companies are actively participating in the siRNA market, with collaborations with MNCs and a focus on innovative delivery methods. The investment recommendation includes companies like HengRui Medicine, Beite, and others in the A-share market, as well as several in the Hong Kong market [4]

Core Insights - Arrowhead Pharmaceuticals focuses on developing medicines for intractable diseases by silencing the genes that cause them, operating in a competitive biopharmaceutical industry alongside peers like Alnylam Pharmaceuticals, ACADIA Pharmaceuticals, and Axsome Therapeutics [1] Financial Performance - Arrowhead Pharmaceuticals has a Return on Invested Capital (ROIC) of 20.84%, significantly higher than its Weighted Average Cost of Capital (WACC) of 9.83%, resulting in a ROIC to WACC ratio of 2.12, indicating effective capital utilization and value creation [2][5] - Alnylam Pharmaceuticals has a ROIC of 13.74% and a WACC of 5.68%, leading to a ROIC to WACC ratio of 2.42, demonstrating efficient capital utilization [3] - ACADIA Pharmaceuticals has the highest ROIC of 23.32% and a WACC of 6.72%, resulting in a ROIC to WACC ratio of 3.47, indicating superior efficiency and growth potential among peers [4][5] - Axsome Therapeutics shows a negative ROIC of -43.39% and a WACC of 5.50%, with a ROIC to WACC ratio of -7.89, highlighting significant inefficiencies in capital utilization [4]

Core Insights - Arrowhead Pharmaceuticals focuses on developing medicines for intractable diseases by silencing the genes that cause them, operating in a competitive biopharmaceutical industry alongside peers like Alnylam Pharmaceuticals, Amicus Therapeutics, ACADIA Pharmaceuticals, and Axsome Therapeutics [1] Financial Metrics Comparison - Arrowhead Pharmaceuticals has a Return on Invested Capital (ROIC) of 20.84%, significantly higher than its Weighted Average Cost of Capital (WACC) of 9.86%, resulting in a ROIC to WACC ratio of 2.11, indicating efficient capital utilization and potential for growth [2] - Alnylam Pharmaceuticals shows a negative ROIC of -10.44% against a WACC of 5.30%, leading to a ROIC to WACC ratio of -1.97, highlighting inefficiencies in capital utilization [3] - Amicus Therapeutics also reports a negative ROIC of -13.65% with a WACC of 6.20%, resulting in a ROIC to WACC ratio of -2.20, indicating challenges in generating returns above its cost of capital [3] - ACADIA Pharmaceuticals stands out with a ROIC of 23.32% and a WACC of 6.74%, yielding a ROIC to WACC ratio of 3.46, suggesting strong capital efficiency and growth potential [4] - Axsome Therapeutics has a notably negative ROIC of -55.37%, far below its WACC of 5.53%, resulting in a ROIC to WACC ratio of -10.02, indicating significant challenges in capital utilization [5][6]

Summary of siRNA Industry Insights Industry Overview - The siRNA drug market is projected to reach $50.3 billion by 2040, indicating a significant growth opportunity in the nucleic acid therapy sector, which is gaining traction as a new drug development direction [1][1][1] Key Insights - siRNA drugs offer high efficiency, low toxicity, and long-lasting effects compared to traditional small molecules and biologics, making them a popular choice in new drug development [1][1][1] - The GalNAc liver delivery platform has matured, showing high delivery efficiency and specificity, becoming the standard for liver-targeted siRNA drugs. Notable targets include PCSK9, AGT, Lp(a), and ApoC3, which have demonstrated therapeutic potential [1][1][1] - There is potential for breakthroughs in extrahepatic delivery systems, with early-stage developments in areas such as muscle, CNS, and ocular applications. Alnylam's C16 delivery platform is showing promise in Alzheimer's disease, while Arrowhead and Wave Life Sciences are exploring fat tissue targets [1][1][1] Market Dynamics - Domestic siRNA companies are positioned to capitalize on the demand for new technologies as traditional chronic disease drugs approach the end of their sales lifecycle. Collaborations with multinational corporations (MNCs) are expected to increase, particularly in liver delivery systems [2][2][2] - The industry outlook is optimistic, with domestic siRNA drugs likely to secure partnerships in popular targets like PCSK9 and Lp(a). New demands in weight loss and CNS delivery are further opening up the market as international giants make breakthroughs [2][2][2] Relevant Companies - A-share listed companies: Yuyuan Pharmaceutical, Frontier Biotech, Fuyuan Pharmaceutical, Bibetech, Sunshine Nuohuo, Chengdu Xian Dao - Hong Kong listed companies: Reebio, and upcoming IPOs such as Jingyin Biotech and Bowe Pharmaceutical - Upstream industry chain participants include WuXi AppTec, Lianhua Technology, Aorite, Lanxiao Technology, Nawei Microbiology, and Jiuzhou Pharmaceutical [2][2][2]